Selcia signs drug discovery agreement with Gilead

Under the contract, Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead‘s liver disease research programmes.

Gilead Research senior vice president William Lee said that they are pleased to announce the continued research collaboration with Selcia in this very important therapeutic area for Gilead.

"Scientists from both companies have interacted well together and have made successful progress against some difficult targets," Lee said.

"We are looking forward to the collaboration delivering candidates for clinical studies in the foreseeable future."

Selcia managing director Hans Fliri said that they look forward to continuing to support Gilead in their search for new drugs to treat liver diseases and in fulfilling their longer term objectives.